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Abstract 
Spasmodic dysphonia (SD) is a focal laryngeal dystonia that affects speech production. It is 
a rare disease that can remain undiagnosed and untreated in many. It usually develops in midlife 
and is socially and occupationally disabling. It can be sub-classified into adductor SD (ADSD), 
abductor SD (ABSD) and mixed SD. In one - third of patients, SD is also associated with vocal 
tremor (SD/VT). This further complicates the diagnosis, as this element of the disease has a more 
variable response to the gold standard of management Botulinum toxin (BoNT) than SD alone. The 
reasons for this are unclear, but a lack of the full understanding of the aetiology, pathophysiology 
and clinical features of SD with or without VT (SD+/-VT) certainly contribute.  
 
Whilst there has been some recent progress made in understanding the brain functional and 
structural alterations of SD, there has been no commensurate progress in understanding the VT 
component of SD/VT. As such this prevents the true understanding of the nature of SD+/-VT, and 
thus improved management of the disorder. Therefore the first aim of this work was to determine 
specific brain abnormalities contributing to both SD and SD/VT, via examining functional and 
structural brain abnormalities in 20 SD vs. 20 SD/VT vs. healthy controls (HV), using functional 
MRI (fMRI) during symptomatic speech production, voxel based morphometry (VBM) and 
diffusion weighted imaging (DWI). This revealed that both SD and SD/VT groups showed 
increased activation in the sensorimotor cortex, inferior frontal (IFG) and superior temporal gyri 
(STG), putamen and ventral thalamus, as well as deficient activation in the inferior parietal cortex 
and middle frontal gyrus (MFG). Common structural alterations were observed in the IFG and 
putamen, which were further coupled with functional abnormalities in both patient groups 
(Coordinates at the peak of significant clusters are given in the AFNI standard Talairach-Tournoux 
space at an FWE-corrected p ≤ 0.05). Abnormal activation in the left putamen was correlated with 
SD onset (r = 0.61, p = 0.004), whereas SD/VT onset was associated with right putaminal 
volumetric changes (r = -0.48, p = 0.032). These and further findings explored in the thesis 
demonstrate that SD and SD/VT, are heterogeneous disorders at different ends of the same clinical 
spectrum, with each disorder carrying a characteristic neural signature, which may potentially help 
the development of differential markers for these two conditions. 
 
The secondary aim of this Masters, was to explore some of the clinical characteristics of 
SD+/-VT. It has been acknowledged anecdotally that the symptoms of both SD and SD/VT respond 
positively to the consumption of alcohol. This has been published in the setting of VT alone, 
however it has never been formally explored in the setting of SD. Therefore the secondary aim of 
this work was to conduct a cross sectional online survey of patients with SD and SD/VT in order to 
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ascertain their degree of alcohol consumption and the effect it has on their symptoms. Of the 531 
patients selected for data analysis the consumption of alcohol was reported by 374 SD (92.1%) and 
109 SD/VT (87.2%) patients. Improvement of voice symptoms after alcohol ingestion was noted by 
227 SD (55.9% of all patients) and 73 SD/VT (58.4%) patients. The stabilizing effect of alcohol 
was reported to be after two drinks in SD patients (p = 0.002), whereas SD/VT symptoms improved 
independent of the consumed amount (p = 0.48). Alcohol may modulate the pathophysiological 
mechanisms underlying abnormal neurotransmission of gamma-aminobutyric acid (GABA) in 
dystonia and as such provide new avenues for novel therapeutic options in these patients.  
 
The final and tertiary aim of this Masters was to further explore the role of sodium oxybate 
Xyrem® – Jazz Pharmaceuticals) in SD+/-VT as a possible novel pharmacological treatment. This 
medication appears to have effects similar to those of alcohol ingestion in SD and VT patients. The 
active metabolite of sodium oxybate, gamma-hydroxybutyric acid (GHB), crosses the blood brain 
barrier and is converted into gamma-aminobutyric acid (GABA). This drug is currently FDA/TGA 
approved for narcolepsy, but it has also been trialed in other ethanol responsive movement disorders 
including post hypoxic myoclonus (PHM), myoclonus dystonia (MD) and essential tremor (ET). 
More recently there was a successful trial of Xyrem® in an open label setting in a SD patient with 
VT. Given the promise of this trial we further examined the role of Xyrem® on three more patients 
with SD. This was undertaken by performing a patient self assessment survey as well as singled 
blinded speech therapy assessment of breaks, harshness and breathiness both pre and post Xyrem® 
administration. Two of the three patients had improvements in patient self-assessment but each of 
the three patients had a different response on single blinded speech therapy assessment. One patient 
had a slight worsening of their breaks (-5.26%), another had a mild improvement (21.0%) and the 
third and final patient had an overwhelming improvement (78.6%). While these results are 
promising, further studies are needed, including a double-blinded randomized controlled trial in 
order to analyze effectiveness. 
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Introduction 
Spasmodic dysphonia (SD) is a task specific focal laryngeal dystonia that affects 
predominately speaking. It has a prevalence of 1/100 000, however it is a condition thought to be 
under-diagnosed and thus inadequately treated. In the first total population study of primary 
dystonia in Iceland the prevalence of SD was 5.9/100 000.(1) The disorder has either a sudden or 
gradual onset and occurs most commonly in the fourth – fifth decade. Women are more likely to be 
affected then men at a ratio of approximately 4:1.(2) SD is of uncertain etiology but it is likely to be 
multi-factorial.  In a small proportion of patients there is clear familial history with a rate of 12% 
reported in the largest treatment series thus far.(3) Genetic mutations have been identified in both 
focal and segmental dystonias, including spasmodic dysphonia, with further research in this field 
ongoing.(4) 
 
The disorder consists of several subtypes including adductor, abductor and mixed spasmodic 
dysphonia. The more common adductor subtype (ADSD) has a strained quality of speech due to 
involuntary spasms of the adductor laryngeal muscles. The less common abductor subtype (ABSD) 
presents with slowed vocal fold closure leading to prolonged voiceless consonants and a breathy 
quality during speaking. Rarely a patient can present with mixed SD, which is a combination of 
both ADSD and ABSD. In approximately one – third of patients, SD will also co – exist with voice 
tremor (SD/VT).(2, 5) This itself is an involuntary oscillation of the laryngeal and pharyngeal 
musculature, resulting in a modulation of pitch and loudness during voice production. Typically, an 
affected patient can not sustain a vowel for longer than 5 seconds.(6) Given the longevity of 
symptoms, a patient’s emotional state can be greatly affected, impacting both workplace 
productivity and social interaction.(7) There is no cure for SD +/- VT, but the current gold standard 
of management is Botulinum toxin (BoNT) injections to either the adductor or abductor laryngeal 
musculature depending on the subtype.(2, 3, 8) Currently the literature shows that ADSD patients 
receive the greatest benefit from BoNT, ABSD a moderate benefit and VT a more unpredictable 
response.(3, 9) In addition to BoNT, the VT component may also be treated with primidone and 
propanolol with variable efficacy.(10) Lastly an alternative to these treatments in some patients is 
surgery, particularly selective laryngeal adductor denervation – reinnervation (SLAD – R) surgery. 
(11) 
 
Features of the aetiology, pathophysiology and phenomenology of SD are still poorly 
understood. Recently some progress has been made in SD, via the utilization of advanced 
neuroimaging modalities such as functional MRI (fMRI), positron emission tomography (PET), 
voxel based morphometry (VBM) and diffusion weighted imaging (DWI) in order to further 
18 
understand the neuropathophysiology of the disease. These studies have identified brain functional 
and structural alterations in SD, particularly in the regions involved in speech production. In 
particular the fMRI studies have consistently found abnormal activity in the primary sensorimotor, 
premotor and sensory association cortices during symptomatic speech tasks.(12-14) During 
asymptomatic tasks there is ongoing altered activation in the primary sensorimotor cortex 
suggesting some alteration in underlying brain structure.(13) An earlier DWI study identified white 
matter changes along the corticobulbar and corticospinal tracts of SD patients and this then guided 
the brain tissue analysis of one postmortem SD patient.(15) Compared to three postmortem healthy 
patients, a reduction of axonal density and myelin content in the genu of the internal capsule was 
found in the SD patient.(15) More recently a combined MRI, fMRI, VBM and cortical thickness 
analysis was done in order to analyze the structure – function relationship in SD patients.(14) In this 
study, gray matter volume (GMV), cortical thickness and brain activation increases were seen in the 
laryngeal primary sensorimotor cortex, inferior frontal gyrus, superior temporal gyrus, middle 
temporal gyrus and cerebellum.(14) Limitations of each of these studies, was the focus on the SD 
patient group as a whole, rather than separation of the disease process into its subtypes and their 
subsequent neuroimaging analysis. As such currently no evidence exists for VT in the presence of 
SD and without entering into the conjecture regarding the diagnosis of tremor in the presence of the 
dystonia the aim was to further understand the neuropathophysiology of these co – existing 
conditions. Therefore the first aim of this Masters was to compare the differences in brain activation 
seen in patients with SD to those with SD/VT via the utilization of fMRI, VBM and DWI. By doing 
so will help to determine the functional and structural organization of the speech controlling 
networks in SD and SD/VT patients versus healthy volunteers as well as in SD versus SD/VT 
patients. The hypothesis is that there will be distinct brain abnormalities present in SD versus 
SD/VT patients, not only because SD/VT patients are clinically different to SD patients, but also 
because they usually have a poorer response to BoNT treatment.(9, 10) Ultimately an improved 
understanding of the neuropathophysiology of SD and SD/VT will result in both the optimized 
diagnosis and management of these patients. 
 
It has also been noticed anecdotally that SD patients with or without VT, have a positive 
modulation of their symptoms due to alcohol. This has been acknowledged in the literature in 
patients with VT alone but not in SD.(9, 10) Unfortunately in other movement disorders it has been 
documented that this has led to the misuse of alcohol in order to self manage this range of 
conditions, but once again no data regarding SD exists.(16) Therefore the second part of this Masters, 
attempts to formalize these anecdotal findings by conducting a prospective cross sectional survey of 
SD and SD/VT patients. This survey was advertised online via the National Spasmodic Dysphonia 
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Association (NSDA), which has reach to SD patients both nationally and internationally. In this 
study key questions were asked regarding alcohol use and its effect on voice symptoms.  The 
working hypothesis is that there will once again be a difference between these two subsets of 
patients, given that anecdotally VT is thought to have more a stabilizing response to alcohol than 
SD. The rationale for exploring this anecdotal affect is that it may provide a pathway to the 
development of future novel therapies for SD and SD/VT patients. 
 
The alcohol study provides a platform to the final part of the Masters Thesis, which 
examines the use of Sodium oxybate (Xyrem® – Jazz Pharmaceuticals) as a novel therapeutic 
treatment for SD. In the United States and Australia this is currently FDA and TGA approved for 
narcolepsy. Its active metabolite, gamma-hydroxybutyric acid (GHB) crosses the blood brain 
barrier and is converted into gamma-aminobutyric acid (GABA). It then exerts some of its major 
pharmacologic effects by acting at GABAB receptors. Its effects at GABAA receptors and other 
aspects of its pharmacology are still unknown.(17) Sodium oxybate has been successfully trialed in a 
single blinded setting in other alcohol responsive movement disorders.(18-20) Furthermore the use of 
this medication has also been extended to spasmodic dysphonia with the promising trial of Xyrem® 
in a single SD patient with vocal tremor (SD/VT).(21) The results of this study suggested that 
Xyrem® may have some use in spasmodic dysphonia not only because of the therapeutic similarity 
to ethanol, but also because the levels of GABA are thought to be deficient in dystonia patients.(22, 
23) These papers were certainly promising, but are somewhat limited by their single blinded nature 
and the possible placebo effect of Xyrem®. However one can not discount the dose dependent 
response to Xyrem®, nor the neuropathophysiological changes seen on post treatment fMRI, thus 
justifying further examination of the drug in ethanol responsive movement disorders. Therefore the 
final and tertiary aim of this Masters proposal is to further explore the clinical effects of Xyrem® 
on SD patients by undertaking an extensive literature review and also to explore the actions of the 
drug on three patients with SD alone. In this group speech was assessed both prior to and after 
Xyrem® intake via a self-assessment patient protocol, as well as via a single blinded speech therapy 
assessment of breaks, harshness and breathiness. The working hypothesis is that an improvement of 
symptoms will be seen in those patients who already see an improvement with alcohol, in both self-
assessment of symptoms as well as in blinded speech therapy assessment. The rationale for this 
study is once again to potentially lead to the development of future novel therapies for SD and 
potentially SD/VT patients, either as an adjunct to BoNT or as a novel therapeutic treatment in its 
own right following further double blinded randomized controlled trials.   
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Chapter 1 – The Neuropathophysiology of SD and SD/VT  
Introduction 
This part of the Masters includes the publication that examined the neuropathophysiology of SD 
and SD/VT via multimodal neuroimaging including fMRI, VBM and DWI. 
 
Neural correlates of dystonic tremor: a multimodal study of voice tremor in spasmodic 
dysphonia.  
Kirke DN, Battistella G, Kumar V, Rubien Thomas E, Choy M, Rumbach A, Simonyan K 
Brain Imaging Behav. 2016 Feb 3 [Epub ahead of print]  
 
Publication Summary 
Specific brain abnormalities of both SD and SD/VT were examined by comparing 20 SD vs. 20 
SD/VT patients vs. 20 healthy controls (HV), using functional MRI (fMRI) during symptomatic 
speech production, voxel based morphometry (VBM) and diffusion weighted imaging (DWI).  
 
Candidates Contribution 
The majority of the data collection, analysis and preparation of the manuscript were performed by 
me. The findings of the paper were presented by myself, Diana N Kirke, as a poster presentation at 
the Society for Neuroscience (SfN) Annual Meeting in Chicago, Illinois October 2015.   
 
Significance of Work 
This study is the first to demonstrate that the majority of functional and structural alterations in SD 
and SD/VT patients compared to healthy controls are shared between these two patient groups. 
Both groups showed increased activation in the sensorimotor cortex, inferior frontal (IFG) and 
superior temporal gyri (STG), putamen and ventral thalamus, as well as deficient activation in the 
inferior parietal cortex and middle frontal gyrus (MFG). Common structural alterations were 
observed in the IFG and putamen, which were further coupled with functional abnormalities in both 
patient groups (Coordinates at the peak of significant clusters are given in the AFNI standard 
Talairach-Tournoux space at an FWE-corrected p ≤ 0.05). This study was also the first to 
demonstrate that each of the SD and SD/VT groups also exhibit a set of focal disorder-specific 
alterations. Abnormal activation in the left putamen was correlated with SD onset (r = 0.61, p = 
0.004), whereas SD/VT onset was associated with right putaminal volumetric changes (r = -0.48, p 
= 0.032). VT severity established a significant relationship with abnormal volume of the left IFG. 
Direct patient group comparisons showed that SD/VT patients had additional abnormalities in MFG 
and cerebellar function and white matter integrity in the posterior limb of the internal capsule. 
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These findings suggest that SD and SD/VT are heterogeneous disorders at different ends of the 
same pathophysiological spectrum, with each disorder carrying a characteristic neural signature, 
which may potentially help development of differential markers for these two conditions. 
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Abstract  
Tremor, affecting a dystonic body part, is a frequent feature of adult-onset dystonia. 
However, our understanding of dystonic tremor pathophysiology remains ambiguous, as its 
interplay with the main co-occurring disorder, dystonia, is largely unknown. We used a 
combination of functional MRI, voxel-based morphometry and diffusion-weighted imaging to 
investigate similar and distinct patterns of brain functional and structural alterations in patients with 
dystonic tremor of voice (DTv) and isolated spasmodic dysphonia (SD). We found that, compared 
to controls, SD patients with and without DTv showed similarly increased activation in the 
sensorimotor cortex, inferior frontal (IFG) and superior temporal gyri, putamen and ventral 
thalamus, as well as deficient activation in the inferior parietal cortex and middle frontal gyrus 
(MFG). Common structural alterations were observed in the IFG and putamen, which were further 
coupled with functional abnormalities in both patient groups. Abnormal activation in left putamen 
was correlated with SD onset; SD/DTv onset was associated with right putaminal volumetric 
changes. DTv severity established a significant relationship with abnormal volume of the left IFG. 
Direct patient group comparisons showed that SD/DTv patients had additional abnormalities in 
MFG and cerebellar function and white matter integrity in the posterior limb of the internal capsule. 
Our findings suggest that dystonia and dystonic tremor, at least in the case of SD and SD/DTv, are 
heterogeneous disorders at different ends of the same pathophysiological spectrum, with each 
disorder carrying a characteristic neural signature, which may potentially help development of 
differential markers for these two conditions. 
 
Keywords: dystonic tremor, laryngeal dystonia, fMRI, TBSS, VBM 
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Introduction 
 Tremor, affecting a dystonic body part, is a frequent feature of adult-onset dystonia with 
prevalence of up to 70% in patients with dystonia.(24-26) Clinically, dystonic tremor (DT) is 
characterized by involuntary rhythmic oscillatory movements and may resemble symptoms of 
dystonia, essential tremor (ET), or Parkinson tremor, oftentimes complicating the diagnosis and 
management of these disorders. Despite the existing consensus statement on tremor(26), there is an 
ongoing debate as to whether DT is a disorder distinct from dystonia and ET or whether these 
disorders are more heterogeneous conditions within the same clinical spectrum.(24, 27, 28) 
 
Several studies have lent support to the concept that DT and ET are pathophysiologically 
distinct disorders by showing that patients with DT, compared to ET, have characteristic EMG 
patterns that are dependent on age of onset of disorder and symptom progression(29), which may be 
associated with increased brainstem excitability(30) and abnormal temporal discrimination(31). A 
recent neuroimaging study examining microstructural brain organization in a mixed group of 
patients with head and limb DT has reported increased gray matter volume and cortical thickness in 
the left sensorimotor cortex as opposed to ET patients who showed atrophy in the anterior 
cerebellar cortex.(32) Collectively, these studies proposed that DT and ET may have different 
courses and pathophysiology and therefore may be considered as clinically separate conditions.  
 
Nevertheless, our understanding of DT phenomenology still remains ambiguous, as its 
interplay with the main co-occurring disorder, dystonia, is largely unknown. Considerable progress 
has been recently made in identification of brain alterations in different forms of dystonia, pointing 
to abnormal function and structure within the basal ganglia-thalamo-cortical and cerebello-thalamo-
cortical circuits.(33, 34) However, the available studies contributed little to complete the 
understanding of DT, which is an integral clinical feature of the large number of dystonia cases, as 
they fell short of examining brain organization in patients with dystonia with and without DT, 
directly.   
 
Here, we used multimodal neuroimaging, including functional MRI (fMRI) during 
symptomatic task production as well as structural voxel-based morphometry (VBM) and diffusion-
weighted imaging (DWI), to investigate similar and distinct patterns of brain function and structure 
in patients with DT of voice (DTv) and isolated spasmodic dysphonia (SD). SD is a form of 
laryngeal dystonia, which predominantly affects speech production, leading to the inability to 
produce certain vowels (adductor form, ADSD) or voiceless consonants (abductor form, ABSD) 
due to involuntary, uncontrolled spasms in the laryngeal muscles. In about one-third of SD patients, 
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dystonic symptoms are associated with DTv, characterized by rhythmic alterations in voice pitch 
and loudness and by the inability to sustain a vowel for more than a few seconds, which 
additionally challenges already impaired vocal communication in SD patients.(5, 10) Previous fMRI 
studies in SD alone have consistently found abnormal activity in the primary sensorimotor, 
premotor and sensory association cortices during symptomatic tasks.(12-14) During asymptomatic 
tasks there is ongoing altered activation in the primary sensorimotor cortex suggesting some 
alteration in underlying brain structure.(13) More recently a combined MRI, fMRI, VBM and 
cortical thickness analysis was done in order to analyze the structure – function relationship in SD 
patients.(14) In this study, gray matter volume (GMV), cortical thickness and brain activation 
increases were seen in the laryngeal primary sensorimotor cortex, inferior frontal gyrus, superior 
temporal gyrus, middle temporal gyrus and cerebellum.(14) 
 
Therefore based on earlier studies in DT vs. ET, as well as on similarities and differences in 
clinical features between SD and DTv, we hypothesized that while SD patients with and without 
DTv would have similar structural and functional alterations within the sensorimotor cortical 
regions, SD patients would have additional abnormalities in the subcortical regions (e.g., putamen) 
and SD/DTv patients would show distinct abnormalities in the cerebellum. 
 
Methods 
Sample Size & Subjects 
To estimate the number of subjects to be included in this study, we reviewed our past fMRI 
study in SD patients, which used similar fMRI experimental design.(13) Significantly increased 
activation intensity was found in the primary somatosensory cortex during production of 
symptomatic syllables in SD patients compared to controls (mean % signal change ± st.dev.: SD vs. 
controls: 0.63 ± 0.16 vs. 0.39 ± 0.23; p ≤ 0.01). Using these values, results of two-tailed t-test 
calculations suggest that a sample size of 15 subjects per group would have 80% power to detect 
group differences at a 0.025 significance level. As such we recruited twenty patients with combined 
SD and VT (hereafter defined as SD/DTv; age 60.0 ± 10.1 years; 18 females/2 males; 10 ADSD/10 
ABSD), 20 patients with isolated SD (age 54.4 ± 8.3 years; 16 females/4 males; 10 ADSD/10 
ABSD), and 20 healthy controls (age 53.8 ± 9.9 years; 16 females/4 males) in order to account for 
the subjects’ dropout possibilities and to increase statistical power for detection of differences 
between groups (see Table 1). All subjects were monolingual native English speakers and right-
handed as determined by the Edinburgh Handedness Inventory. No participant had any past or 
present history of any neurological (except SD and SD/DTv in patient groups), psychiatric or 
laryngeal problems. All SD and SD/DTv subjects were fully symptomatic and did not have dystonia 
26 
or tremor in other body parts. The diagnosis of DTv was made at the same time as the diagnosis of 
SD, although there is a possibility that these two disorders might not have started concurrently. 
Patients receiving botulinum toxin treatment participated in the study only at the end of their 
treatment cycle, when fully symptomatic, at least 3 months post injection. There were no significant 
differences between subject groups in their age, gender, disorder onset, duration, or severity (all p ≥ 
0. 06) (see Table 1). Prior to participation, all subjects gave written informed consent, which was 
approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai. 
 
Table 1. Demographics of participants  
Comparisons were made between each patient group and controls as well as between the patient 
groups using two-sample t-test at a corrected p ≤ 0.05. SD – spasmodic dysphonia, SD/DTv – 
spasmodic dysphonia and dystonic tremor of voice, ADSD – adductor spasmodic dysphonia, ABSD 
– abductor spasmodic dysphonia, st. dev. – standard deviation, N/A – not applicable.   
 
Data acquisition  
All scans were acquired on a 3.0 T Philips MRI scanner equipped with an 8-channel head 
coil. Whole-brain fMRI data were obtained using a gradient-weighted echo planar imaging (EPI) 
pulse sequence (sparse-sampling event-related design: TR = 2s per volume and 10.6s between 
volumes, TE = 30ms, FA = 90°, FOV = 240mm, voxel size = 3.75 x 3.75mm, 36 slices with 4-mm 
slice thickness) and blood oxygen level dependent (BOLD) contrast. Experimental design included 
ten SD- and DTv-symptom provoking sentences (for example, “Are the olives large?”, “He is 
Number of subjects SD SD/DTv Controls p-value 
20 20 20 
Age 
(years; mean±st. dev.) 
54.4±8.3 
 
60.0±10.1 
 
53.8±9.9 
 ≥ 0.06 
Gender 
(female/male) 16/4 18/2 16/4 ≥ 0.39 
Dystonia subtype 10 ADSD 10 ABSD 
10 ADSD/VT 
10 ABSD/VT N/A N/A 
Onset 
(years; mean±st. dev.) 
40.7±11.8 
 
47.6±10.0 
 N/A 0.27 
Duration (years) 
(years; mean±st. dev.) 13.75±8.91 12.45±8.94 N/A 0.65 
SD severity 
(voice breaks; 
mean±st. dev.) 
2.95±1.02 2.70±0.86 N/A 0.42 
DTv severity 
(mean±st. dev.) N/A 54.2±26.3 N/A N/A 
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hiding behind the house”), which were produced by all subjects one at a time. Subjects’ speech 
production during the fMRI session was audio recorded for later analysis, which revealed that 
production of all sentences was symptomatic in all patients. To minimize head movements during 
scanning, subjects' head was tightly cushioned, and they were instructed to remain motionless 
throughout the scan; possible movements were monitored online. High-order shimming was 
performed before EPI acquisition to minimize EPI distortions and ensure homogeneity of the 
magnetic field within the scanner.  
 
A structural high-resolution T1-weighted MRI was acquired in each subject using 3D 
magnetization prepared rapid acquisition gradient echo sequence (3D-MPRAGE: TR = 7.5ms, TE = 
3.4ms, TI = 819ms, FA = 8°, FOV = 210mm, 172 slices with 1mm slice thickness) and used as an 
anatomical reference for fMRI data and for VBM analysis. Diffusion-weighted images (DWI) were 
acquired using a single-shot spin-echo EPI sequence with 54 contiguous axial slices along 60 
noncollinear directions, in addition to one volume without diffusion encoding (b0 image) (TR = 
13,000 ms, FOV = 240 mm, matrix = 96 x 96 mm zero-filled to 256 x 256 mm, slice thickness 2.4 
mm, b = 1000s/mm2). 
 
Data analysis 
Data analysis was performed using a combination of AFNI, FSL and SPM8 software 
packages. All images prior to analysis were anonymized and randomized and then following this 
blindly assessed by a team of experienced neuroimaging scientists. For functional datasets, the first 
four volumes in each subject's time series were discarded to account for the magnetization 
equilibrium. All images were visually inspected for motion artifacts. To assess head motion in each 
subject, we calculated the root mean square (RMS) for each individual across the entire fMRI 
session as well as during speech production and resting, separately. Two-sample t-tests between the 
subject groups showed no significant differences in head motion at p ≥ 0.43 as well as no 
significant differences between the motion during task production and resting at p ≥ 0.94. 
Therefore, no data were excluded from the study due to the motion artifacts. Following the standard 
pre-processing and spatial smoothing of EPI data with a 4-mm Gaussian filter, a single regressor for 
each task was convolved with a canonical hemodynamic response function and entered into a 
multiple regression model to predict the observed BOLD response. To correct for possible residual 
head motions, six motion parameter estimates were included as covariates of no interest, and 
quadratic polynomials in time were used to model baseline drifts for each imaging run. The 
resultant images were spatially normalized to the AFNI standard Talairach-Tournoux space using 
the TT_N27 template and submitted to a two-way analysis of variance (ANOVA) with subject as a 
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random factor and the group and task as fixed factors. Statistical analyses were performed to 
identify (1) shared abnormalities in SD and SD/DTv patients vs. controls, and (2) distinct 
abnormalities between SD and SD/DTv patient groups at family-wise (FWE) corrected p ≤ 0.05. 
 
The VBM8 toolbox in SPM8 software running on MATLAB version 8.4 (Mathworks, MA) 
was used to identify gray matter volumetric abnormalities between the groups. Whole-brain gray 
matter segmentation was performed using the unified segmentation approach, which was further 
refined by applying adaptive a posteriori estimations and a hidden Markov Random Field model. 
Gray matter probability maps were non-linearly registered to the SPM standard Montreal 
Neurological Institute (MNI) space using the diffeomorphic nonlinear registration tool (DARTEL) 
to improve inter-subject registration through spatial normalization. To assess voxelwise statistical 
differences between all patients and controls, as well as between SD and SD/DTv patients directly, 
we performed two independent t-tests, including age and gender as covariates, at FWE-corrected p 
≤ 0.05. 
 
Diffusion-weighted data were pre-processed with FSL FMRIB Diffusion Toolbox (FDT), 
which corrected eddy current distortion and subject movements via an affine registration to b0 
reference. Fractional anisotropy (FA) values were calculated using nonlinear fitting and submitted 
to a Tract-Based Spatial Statistics (TBSS) pipeline to perform statistical comparisons of group FA 
values in patients and controls. Individual FA maps were registered to the standard MNI template 
using b-spline nonlinear registration, and an alignment-invariant tract representation known as the 
mean FA skeleton (threshold 0.2) was generated. Each subject’s FA map was projected onto the 
mean FA skeleton, resulting in a 4D skeletonised FA volume. Inferential statistics was performed 
using t-tests between the examined groups at FWE-corrected p ≤ 0.05.  
 
In order to assess the relationships between abnormal gray matter structure and function in SD 
and SD/DTv patients, we performed a conjunction analysis using the significant clusters identified 
in the VBM and fMRI datasets at a group level. Similar to the procedures described earlier(14, 35, 36), 
each patient’s VBM dataset (i.e., a smoothed modulated for the non-linear components DARTEL 
warped segmented gray matter image) was transformed from the MNI standard space into the 
Talairach-Tournoux standard space using @auto_tlrc program of AFNI software to match the space 
transformation of the fMRI dataset (i.e., beta coefficients of functional activation during 
symptomatic sentence production). To create a single 3D+subjects volume for each of the VBM 
and fMRI datasets, the respective images were concatenated across all subjects in each group. The 
resultant single volumes of VBM datasets were resampled to match the same grid spacing and 
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orientation of the fMRI dataset. To identify the relationships between VBM and fMRI 
abnormalities, Pearson’s correlation coefficients were computed between the corresponding voxels 
of VBM and fMRI datasets in each patient group using AFNI’s 3dTcorrelate program. The resultant 
maps were thresholded at an FWE-corrected p ≤ 0.05.  
 
Clinical characteristics of SD and SD/DTv were evaluated using the patients’ speech 
recorded during the fMRI session. These recordings were anonymized, randomized, and blindly 
rated by an experienced speech-language pathologist. SD symptoms were assessed by counting the 
number of SD-characteristic voice breaks in each sentence; DTv symptoms were evaluated using a 
visual analog scale of severity that used three gradation indicators along a 100-mm line (normal, 
modulates voice, offsets voice), with distance in mm used to describe the degree of deviancy from 
normal. Information on the disorder onset and duration was obtained during history and physical 
examination in each patient. Relationships between SD and SD/DTv symptom severity, disorder 
onset and duration were assessed in each patient group separately using Pearson’s correlation 
coefficients at p ≤ 0.05.  
 
Results 
Shared brain abnormalities in SD and SD/DTv 
During symptomatic speech production, both SD and SD/DTv groups, compared to healthy 
controls, showed significantly increased cortical activation in the bilateral primary sensorimotor 
cortex, left premotor cortex, inferior frontal (IFG) and superior temporal (STG) gyri, right insula, 
parietal operculum and supplementary motor area (SMA), as well as subcortically in the left 
putamen and bilateral ventral thalamus (see Fig. 1A-I, Table 2). Conversely, deficient activation in 
all patients compared to healthy controls was found in the right inferior parietal cortex (IPC) and 
middle frontal gyrus (MFG) (see Fig. 1A-I, Table 2). Structurally, SD and SD/DTv groups, 
compared to controls, showed gray matter volumetric increases in the left IFG, bilateral putamen 
and left pallidum (see Fig. 1A-II, Table 2), as well as increased fractional anisotropy in the white 
matter underlying the left IFG (see Fig. 1A-III, Table 2). 
 
Figure 1. A) Common functional and structural brain differences in SD and SD/DTv patients 
compared to healthy controls. Regions of abnormal functional activation during symptomatic 
speech production (I), gray matter volume (II) and white matter integrity (III) in SD and SD/DTv 
patients compared with controls are shown on a series of axial and sagittal slices in an AFNI 
standard Talairach-Tournoux space. (B) Distinct alterations in brain function (I) and white matter 
integrity (II) between SD and SD/DTv patients are shown on a series of axial slices in the standard 
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space. The color bars represent the t-score. PT – patients; HV – healthy volunteers; SD – spasmodic 
dysphonia; SD/DTV – spasmodic dysphonia with dystonic tremor of voice. 
 
 
 
 
Table 2. Differences in brain function and structure in SD and SD/DTv  
Anatomical regions Cluster peak coordinates (x, y, z) Cluster peak t level 
Functional activity during symptomatic speech production 
SD and SD/DTv < Controls 
L/R primary sensorimotor 
cortex 
-40, -14, 34 
44, -13, 29 
4.6 
5.3 
L premotor cortex -49, -9, 44 5.4 
L inferior frontal gyrus -49, 1 6 8.2 
L superior temporal gyrus -57, -27, 6 5.7 
L putamen -25, -7, 0 4.8 
L/R thalamus -15, -21, -4 
15, -19, -2 
4.9 
5.3 
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Coordinates at the peak of significant clusters are given in the AFNI standard Talairach-Tournoux 
space at an FWE-corrected p ≤ 0.05. L - left; R - right. 
 
Distinct brain abnormalities between SD and SD/DTv 
Direct comparisons between the two patient groups showed that SD/DTv had additional 
functional alterations in the right MFG and right cerebellum (lobule VIIa) and structural white 
matter abnormalities in the right posterior limb of the internal capsule (see Fig. 1B-I,II; Table 2). 
The only SD-specific difference was found in the white matter integrity of the right genu of the 
internal capsule, which was in line with the previous findings in SD patients (see Fig. 1B-II, Table 
2).(15) No statistically significant differences in gray matter volume were found between the SD and 
SD/DTv patients.  
 
Structure-function interactions in SD and SD/DTv 
 Both SD and SD/DTV patients groups showed an overlap between the significant clusters of 
increased activation and increased gray matter volume in the bilateral putamen and left IFG (see 
Fig. 2I-A, II-A). In the SD group, volumetric changes were correlated positively with the activation 
in the right putamen (r = 0.64, p = 0.003) and negatively with the activation in the left IFG (r = -
R insula 41, 11, 4 6.3 
R parietal operculum  53, -7, 12 7.1 
R supplementary motor area 5, -3, 58 4.7 
SD and SD/DTv > Controls 
R inferior parietal cortex  45, -53, 22 5.4 
R middle frontal gyrus 25, 21, 46 4.7 
SD/DTv > SD 
R middle frontal gyrus  41, 37, 22 5.1 
R cerebellum (lobule VIIa) 21, -71, -22 3.9 
Gray matter volume 
SD and SD/DTv > Controls 
L inferior frontal gyrus  -45, 9, 24 4.2 
L/R putamen -30, -9, -5 
30, 5, 1  
33, -12, 0 
3.0 
3.3 
3.3 
L pallidum -16, -7, 0 3.8 
White matter integrity 
SD and SD/DTv > Controls   
L inferior frontal gyrus -36, 7, 19 2.6 
SD > SD/DTv 
R genu of the internal capsule 16, 7, 8 2.2 
SD/DTv > SD 
R posterior limb of the 
internal capsule 
21, -13, 1 2.6 
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0.45, p = 0.047) (see Fig. 2I-B). In addition, activation of the left putamen was positively correlated 
with the age of SD onset (r = 0.61, p = 0.004) (see Fig. 2I-C). There were no significant correlations 
between structural/functional alterations and SD severity or duration (all r < 0.07, p > 0.77).  
In the SD/DTv group, gray matter volume showed significant negative relationship with 
abnormal activation in the left putamen (r = -0.59, p = 0.006) and significant positive relationship 
with abnormal activation in left IFG (r = 0.56, p = 0.01) (see Fig. 2II-B). Furthermore, gray matter 
volumetric abnormalities in the right putamen were negatively correlated with the age of SD/DTv 
onset (r = -0.48, p = 0.032) (see Fig. 2II-C); abnormal volume of the left IFG showed a negative 
relationship with dystonic voice tremor (r = -0.47, p = 0.037) (see Fig. 2II-D). Again, no significant 
relationships were observed between structure/function alterations, SD/DTv severity (i.e., voice 
breaks and tremor) and its duration (all r < -0.20, p > 0.39). 
 
Figure 2. Correlations between abnormal function, structure and clinical characteristics of SD (A) 
and SD/DTv (B). Panels I-A and II-A depict the overlap between significant clusters of functional 
and gray matter volumetric abnormalities identified in the comparison of SD and SD/DTv with 
healthy controls on a series of axial slices in an AFNI standard Talairach-Tournoux space. Panels 
II-B-C and II-B-D show correlations disorder onset and severity with the significant clusters of 
overlap.  
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Discussion  
Our study demonstrated that the majority of functional and structural alterations in SD and 
SD/DTv patients compared to healthy controls are shared between these two patient groups (see 
Fig. 3). However, each of SD and SD/DTv groups also exhibited a set of focal disorder-specific 
alterations. These findings suggest that dystonia and dystonic tremor, at least in the case of SD and 
SD/DTv, are heterogeneous disorders at different ends of the same pathophysiological spectrum, 
with each disorder carrying a characteristic neural signature, which may potentially help 
development of differential markers for these two conditions. 
 
Figure 3. A schematic diagram summarizing the main findings of functional and structural 
abnormalities in patients with SD and SD/DTv. The middle panel shows the alterations of brain 
function and structure that are common between the two disorders; the right and left panels show 
abnormalities that are characteristic to dystonia and dystonic tremor, respectively. The arrow 
signifies the presence of shared abnormalities by SD and SD/DTv as well as the presence of 
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disorder-specific alterations. L – left; R – right; F – functional abnormality; G – abnormal gray 
matter volume; W – abnormal white matter integration. 
 
Common to both SD and SD/DTv, neural abnormalities were observed within the basal 
ganglia and thalamus as well as in the cortical regions responsible for sensorimotor processing, 
planning and execution of motor commands. Specific to SD and SD/DTv symptomatology, these 
brain regions are also known to control different stages of speech production, which is affected in 
patients with both disorders. Alterations in the majority of these brain regions have been previously 
reported across different forms of dystonia and are thought to contribute to dystonia 
pathophysiology.(33, 34) Therefore, our findings point to likely shared pathophysiological 
mechanisms related to impaired speech control in SD and SD/DTv.  
 
Among these, the IFG and putamen were the only regions that showed strong associations 
between abnormally increased activity, gray matter volume, and underlying white matter 
alterations. The putamen has been historically known to play an important role in the 
pathophysiology of dystonia(37, 38), and its functional, structural and dopaminergic abnormalities 
have been previously reported in SD.(12-15, 39) The putamen receives heavy projections from the 
laryngeal motor cortex(40), and its lesioning has been associated with SD symptom manifestation(41). 
In SD patients, we observed a positive structure-function relationship in the right putamen, whereas 
the later onset of isolated SD was associated with the greater extent of abnormal increases of left 
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putaminal activation. In SD/DTv patients, these relationships were somewhat reversed, with the left 
putamen showing a positive correlation between abnormal structure and function and younger 
SD/DTv patients exhibiting greater gray matter volume in the right putamen. Such a left/right 
dissociation of putaminal involvement in SD and SD/DTv may be due to different roles this 
structure plays in the control of speech production. The left putamen was shown to have greater 
activity during initiation and execution of overt vs. silent speech(42) with increased demands on the 
articulatory system(43) and slower production rates.(44) On the other hand, the right putamen was 
found to suppress right frontal activation to reduce interference during speech production, leading 
to left lateralized activation in a number of brain regions, including the IFG. (45) These findings, 
although regionally similar but physiologically disparate, indicate the critical involvement of the 
putamen in the development of both SD and SD/DTv symptoms, while also suggesting a presence 
of somewhat different mechanisms underlying the progression of these two disorders. Although 
neuroimaging modalities generally lack the ability to clearly distinguish between primary and 
compensatory brain alterations, our findings of associations between the disorder onset and 
putaminal abnormalities speak to importance of this structure from the early stages of symptom 
manifestation.  
 
Another structure that showed correlations between functional and structural abnormalities 
in both SD and SD/DTv patients was the left IFG. This region is known to be involved in an array 
of preparatory processes to speech motor execution, including sound categorization, discrimination 
and phonological decisions on sound content of words(46, 47), processing of syllabic order(48), 
semantic retrieval(49, 50), covert articulatory planning and translating speech into articulatory code. 
(51, 52) In our patient cohorts, coupling between functional and structural abnormalities in the IFG 
may reflect symptomatology of SD and SD/DTv, which is associated with continuous struggles 
with the choice of words in order to avoid or minimize SD-characteristic voice breaks and to 
accurately map articulatory planning to speech motor output due to both voice breaks and tremor. 
Furthermore, the observed association between the left IFG gray matter volumetric changes and 
DTv severity suggests that evaluation of this structure may be considered for the assessment of 
dystonic tremor severity and possible treatment responses. Taken together, our data show that SD 
and SD/DTv may share common pathophysiological mechanisms related to impaired speech 
control.  
 
However, direct comparisons between the SD and SD/DTv groups revealed specific, 
disorder-characteristic alterations present in each group (see Fig. 3). While both disorders appeared 
to follow a similar pathophysiological trajectory, brain abnormalities in SD/DTv enhanced and 
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complimented those present in SD alone. Compared to SD patients, SD/DTv patients exhibited 
greater extent of functional abnormalities in the right MFG and cerebellar lobule VII as well as 
white matter changes in the right posterior limb of the internal capsule at the junction of the 
corticospinal/corticopontine tracts and superior thalamic radiation. The right MFG is known to be 
involved in processing and control of such executive functions as searching the semantic network 
and increased word retrieval effort.(53, 54) Structurally, the MFG establishes a direct link with the 
cerebellum via the thalamus(55), and its activity is accompanied by cerebellar activation, including 
of the lobule VII.(56, 57) It is therefore not surprising that SD/DTv patients had distinct abnormalities 
in both MFG and cerebellar lobule VII. Instead, this finding suggests that patients with DTv 
component had abnormality along the entire cerebello-thalamo-prefrontal executive pathway in 
addition to widespread abnormalities within the sensorimotor system.  
 
The presence of cerebellar changes in SD/DTv patients may also raise the possibility of a 
similarity with essential tremor (ET), where this structure is thought to be dysfunctional.(58-61) 
Current hypotheses of tremor pathogenesis include histopathological changes in the cerebellum, 
aberrant oscillations within the cerebello-thalamo-cortical network, and/or impaired GABAergic 
discharge. Some have suggested that DT may be distinct to ET, based on phenotypic and 
neurophysiological differences between the two disorders(24), while others proposed that these 
disorders may be more intermixed.(27, 62, 63) As our current findings in SD and SD/DTv patients 
demonstrate that dystonia and dystonic tremor may be more heterogeneous than separate disorders 
(see Fig. 3), DTv is likely positioned in-between ET and dystonia based on its clinical 
symptomatology resembling both disorders and brain abnormalities common to both ET and 
dystonia. Yet, distinct brain functional and structural alterations that were observed in patients with 
DTv may be important for future development of neuroimaging biomarkers of this disorder and 
furthermore thus help identify treatment opportunities targeting specific brain abnormalities. 
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Chapter 2 – The Clinical Effects of Alcohol on SD and SD/VT 
Introduction 
This part of the Masters includes the publication that examined the clinical effects of alcohol on SD 
and SD/VT via a large online-based prospective survey. 
 
Alcohol responsiveness in laryngeal dystonia: a survey study. 
Kirke DN, Frucht SJ, Simonyan K. J Neurol 2015 Jun;262(6):1548-56. 
 
Publication Summary 
A large prospective online cross sectional survey based on Research Electronic Data Capture 
(REDCapTM) was distributed to patients with SD and SD/VT via the National Spasmodic 
Dysphonia Association (NSDA), which has both national and international reach. A total of 641 
participants were registered, 531 were selected for data analysis, and 110 were excluded because of 
unconfirmed diagnosis. Of these a total of 406 patients (76.5%) had SD and 125 (23.5%) had SD 
and voice tremor (SD/VT). 
 
Candidates Contribution 
The majority of the data collection, data analysis and preparation of the manuscript were performed 
by me. The findings of the paper were presented by myself, Diana N Kirke, as a poster presentation 
at the Combined Otolaryngology Spring Meeting (COSM) in Boston, Massachusetts April 2015. 
 
Significance of Work 
This study was the first to formalize the long acknowledged anecdotal findings that alcohol has a 
positive modulating effect on both SD and SD/VT symptoms. The consumption of alcohol was 
reported by 374 SD (92.1%) and 109 SD/VT (87.2%) patients. Improvement of voice symptoms 
after alcohol ingestion was noted by 227 SD (55.9% of all patients) and 73 SD/VT (58.4%), which 
paralleled the improvement observed by patient’s family and/or friends in 214 SD (57.2%) and 69 
SD/VT (63.3%) patients. The benefits lasted 1-3 hours in both groups with the maximum effect 
after 2 drinks in SD patients (p = 0.002), whereas SD/VT symptoms improved independent of the 
consumed amount (p = 0.48). Our data suggest that isolated dystonic symptoms, such as in SD, are 
responsive to alcohol intake and this responsiveness is not attributed to the presence of VT, which is 
known to have significant benefits from alcohol ingestion. Alcohol may modulate the 
pathophysiological mechanisms underlying abnormal neurotransmission of gamma-aminobutyric 
acid (GABA) in dystonia and as such provide new avenues for novel therapeutic options in these 
patients. 
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Abstract 
Laryngeal dystonia (LD) is a task-specific focal dystonia of unknown pathophysiology 
affecting speech production. We examined the demographics of anecdotally reported alcohol use 
and its effects on LD symptoms using an online survey based on Research Electronic Data Capture 
(REDCapTM) and National Spasmodic Dysphonia Association’s patient registry. From 641 
participants, 531 were selected for data analysis, and 110 were excluded because of unconfirmed 
diagnosis. A total of 406 patients (76.5%) had LD and 125 (23.5%) had LD and voice tremor 
(LD/VT). The consumption of alcohol was reported by 374 LD (92.1%) and 109 LD/VT (87.2%) 
patients. Improvement of voice symptoms after alcohol ingestion was noted by 227 LD (55.9% of 
all patients) and 73 LD/VT (58.4%), which paralleled the improvement observed by patient’s 
family and/or friends in 214 LD (57.2%) and 69 LD/VT (63.3%) patients. The benefits lasted 1-3 
hours in both groups with the maximum effect after 2 drinks in LD patients (p = 0.002), whereas 
LD/VT symptoms improved independent of the consumed amount (p = 0.48). Our data suggest that 
isolated dystonic symptoms, such as in LD, are responsive to alcohol intake and this responsiveness 
is not attributed to the presence of VT, which is known to have significant benefits from alcohol 
ingestion. Alcohol may modulate the pathophysiological mechanisms underlying abnormal 
neurotransmission of γ-aminobutyric acid (GABA) in dystonia and as such provide new avenues for 
novel therapeutic options in these patients.  
 
Keywords: focal dystonia, tremor, alcohol use 
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Introduction  
Laryngeal dystonia (LD), or spasmodic dysphonia, is a task-specific focal dystonia affecting 
predominantly speaking and occasionally singing. Typically, LD develops in the fourth to fifth 
decade with either sudden or gradual symptom onset.(64) LD is a relatively rare disorder with the 
prevalence up to 5.9/100,000 in general population(1), which preferentially affects more women than 
men with the ratio of about 4:1.(2, 64, 65) LD most often presents as an adductor type (ADLD), which 
is characterized by involuntary spasms in the adductor laryngeal muscles, leading to the forceful 
closure of vocal folds, breaks on vowels and strained, strangled quality of voice. Less common 
form of LD is the abductor type (ABLD), during which slowed vocal fold closure leads to breathy 
voice breaks, prolonged voiceless consonants, and excessive breathiness during speaking. Rarely, 
both types of LD occur in the same individual. About one-third of LD patients are known to 
develop action-induced voice tremor (VT), which further complicates the diagnosis and 
management of this disorder.(2, 5) The current gold standard treatment of LD is botulinum toxin 
(BoNT) injections into the laryngeal muscles.(3, 8, 64) However, BoNT injections are not beneficial 
for all forms of LD as it is estimated that 90% of ADLD patients receive 90% benefit and only 10% 
of ABLD patients receive 70% benefits, whereas co-occurring VT has an unpredictable response.(9, 
10, 64, 66) In addition, BoNT injections are relatively expensive and must be typically repeated every 
3-4 months throughout a patient’s life, which may lead to both psychological and financial burden 
for a patient.(67)  
 
One of the contributing factors to limited therapeutic interventions in these patients is our 
lack of full understanding of LD clinical phenomenology, etiology and pathophysiology. To this 
end, an interesting clinical observation in some LD and almost all VT patients is marked 
improvement of their symptoms after alcohol ingestion. LD and VT are not unique in this regard as 
several other movement disorders, including essential tremor, myoclonus-dystonia, and posthypoxic 
myoclonus, are known to improve with alcohol intake, which sometimes leads to the misuse of 
alcohol in order to self manage this range of disorders.(16) Despite the growing evidence of potential 
therapeutic effects of alcohol in dystonia(19, 68-72), our knowledge about its effects remains scarce. In 
order to characterize the demographics of alcohol use and symptom responsiveness in patients with 
isolated dystonia, we analyzed the responses to an online survey in a large population of LD 
patients. As a secondary aim, we compared our results in LD patients to the findings in LD/VT 
patients because VT has been already known to benefit from alcohol intake.(9, 10) Based on our prior 
clinical observations, we hypothesized that LD patients will have significant benefits of alcohol on 
their voice symptoms and these will be independent from improved symptoms of VT. 
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Methods 
All participants were recruited through the National Spasmodic Dysphonia Association’s 
(NSDA) registry via the email invitations to complete an online survey. The NSDA staff member, 
who contacted the potential participants, was requested to send the online survey invitations only to 
the individuals who identified themselves as patients with LD or LD/VT. The survey was 
administered using Research Electronic Data Capture (REDCapTM) hosted at the Icahn School of 
Medicine at Mount Sinai (73) and was active online for completion for 3 weeks. REDCapTM is a 
secure, web-based application designed to support data capture for research studies, providing: 1) 
an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and 
export procedures; 3) automated export procedures for seamless data downloads to common 
statistical packages, and 4) procedures for importing data from external sources. The survey 
included questions in lay English language pertaining to the use of alcohol and its effects on voice 
symptoms (see Table 1). The questions were designed by one of the authors (SJF) based on similar 
questions asked in our clinic, then cross-checked and modified by another author (KS), and mock-
completed and refined by the laboratory members without a prior knowledge of the survey 
questions before actual data collection. When patient survey data were downloaded from 
REDCapTM, all responses were checked by two independent members of the laboratory (including 
DNK) and any missing values were followed up on and checked with the survey participants, 
whenever possible. All participants provided written online informed consent, which was approved 
by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai.  
 
Table 1. REDCapTM online survey questionnaire 
1. Have you been diagnosed by an ear, nose 
and throat physician (ENT), speech-
language pathologist or neurologist with 
(select all that apply)  
 
 
- Laryngeal dystonia, adductor type  
- Laryngeal dystonia, abductor type  
- Laryngeal dystonia, mixed type  
- Voice tremor  
– Muscle Tension Dysphonia 
 
2. Have you ever received any of the 
following treatment (select all that apply)  
 
 
 
 
 
 
- Botulinum toxin injections  
- Voice and speech therapy  
- Had laryngeal surgery  
- Had deep brain stimulation (DBS)  
- Other medications  
- None of the above 
3. If you receive botulinum toxin injections, 
how much do your injections help?  
 
 
 
- A lot 
- A little  
- Not at all 
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4. How satisfied are you with your current 
treatments for your voice (including 
medications, therapy and injections)?  
 
 
 
 
- Very satisfied  
- A little satisfied  
- Not satisfied 
 
 
5. How often do you drink alcohol?  
 
 
 
  
  
- Daily 
- Weekly  
- Occasionally  
- Only on special occasions  
- I do not drink alcohol 
 
6. How much do you typically drink when 
you do drink alcohol? (1 drink = 1 glass of 
wine = 1 bottle of beer = 1 shot of hard 
alcohol)  
 
 
 
 
- 1 drink  
- 2 drinks  
- > 2 drinks 
 
 
 
7. Have you or a family member or friend 
noticed a change in your voice when you 
drink alcohol? 
- Yes  
- No 
 
8. What is the effect of alcohol on your voice? 
 
 
 
- My voice sounds better  
- My voice sounds worse  
- I do not notice any changes in my voice 
9. If you voice sounds better, how much better 
does it get? 
 
- Slightly  
- Mildly  
- A lot 
 
10. How much alcohol does it take to see the 
most benefit in your voice? 
 
 
 
- 1 drink  
- 2 drinks  
- > 2 drinks 
 
11. Do you notice that drinking more makes 
your voice better? 
 
 
- Yes  
- No 
 
12. How long does the effect alcohol last? 
 
 
 
 
- < 1 hour  
- 1 – 3 hours  
- > 3 hours 
 
13. How well do you tolerate alcohol? 
 
 
- Well  
- OK  
- Poorly 
14. Have you used alcohol to help you with 
your voice in a social or professional 
situation? 
- Yes, always 
- Sometimes  
- Never 
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15. If a medication were available that might 
help your voice, would you consider taking 
it? 
 
 
- Yes  
- No 
 
16. Neurological problems (including but not 
limited to other types of dystonia, 
Parkinson’s disease, Alzheimer’s disease, 
brain tumor, stroke, etc.) 
- Yes  
- No 
 
17. Psychiatric problems (including but not 
limited to major depression, bipolar 
disorder, schizophrenia, etc.) 
 
- Yes  
- No 
 
 
18. Any other major medical problems?                       
 
 
 
 
 
- Yes  
- No 
 
19. Do you have any relatives with history of 
(select all that apply)? 
 
 
 
 
 
 
 
 
- Laryngeal dystonia  
- Other primary dystonias (e.g., blepharospasm, 
cervical dystonia, hand dystonia, 
oromandibular dystonia)  
- Tremor (e.g., voice, hand, head)  
- Other movement disorders (e.g., Parkinson’s 
disease)  
- None of the above 
20. What is your gender?  - Male - Female
 
21. How old are you? 
 
 
 
 
Out of 2,024 individuals who read the NSDA email inviting to the survey participation, a 
total of 641 subjects (31.6%) completed the online survey. Among these, 531 subjects (26.2% of 
total) were included in further data analysis and 110 subjects (5.4% of total) were excluded because 
of incomplete responses and the diagnosis not confirmed or associated with LD and/or VT. The 
final participants were followed up to confirm that they were diagnosed with LD or LD/VT by an 
otolaryngologist, neurologist and/or a speech-language pathologist and that their diagnosis was 
documented using fiberoptic nasolaryngoscopy. Within-group effect of alcohol use on LD or 
LD/VT symptoms was assessed using a single proportion test or one-way chi-square test of 
association, wherever appropriate, at a Bonferroni corrected p ≤ 0.0045 to account for multiple 
comparisons (0.05/11 comparisons). As a secondary aim, we used two-way chi-square test at a 
corrected p ≤ 0.0045 to examine the differences of the alcohol effect between LD and LD/VT 
groups. All statistical analysis was performed using Systat12 (Systat Software, San Jose, CA).  
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Results 
Among 531 online survey participants, 406 patients (age: 57.3±13.5 years old) were 
diagnosed with LD and 125 patients (age: 65.2±12.2 years old) were diagnosed with LD/VT (see 
Table 2). The majority of participants were females with the ratio of 3:1 in the LD group and 7:1 in 
the LD/VT group. The predominant subtype in each group was ADLD with 262 patients (64.5%) in 
the LD group and 75 patients (60.0%) in the LD/VT group. In addition, 10.6% of LD patients and 
15.2% of LD/VT patients had at least one other family member affected with LD and/or other forms 
of dystonia. The majority of patients (83.0% LD and 88.8% LD/VT) received BoNT injections to 
manage their voice symptoms; however, only 55.5% of these LD patients and 35.1% of LD/VT 
patients were ‘a lot’ satisfied with this treatment (see Table 2). Other treatment options included 
voice and speech therapy in 67.7% of LD and 67.2% of LD/VT patients; oral medications in 17.5% 
of LD and 34.4% of LD/VT patients; laryngeal surgery in 5.4% of LD and 7.2% of LD/VT patients, 
and deep brain stimulation (DBS) in 1 patient with LD/VT. The vast majority of patients (96.1% 
LD and 94.4% LD/VT) expressed the willingness to try a new medication if it were available (see 
Table 4). 
 
Table 2. General patient demographics 
 LD LD/VT Total patients 
 406 (100%) 125 (100%) 531 (100%) 
Gender 
Male 95 (23.4) 13 (10.4) 108 (20.3) 
Female 282 (69.5) 93 (74.4) 375 (70.6) 
No response 29 (7.1) 19 (15.2) 48 (9.0) 
Age 
Mean ± st. dev. 57.3 ± 13.5 65.2 ± 12.2 59.0 ± 13.6 
Subtype 
Adductor 262 (64.5) 75 (60.0) 337 (63.5) 
Abductor 93 (22.9) 21 (16.8) 114 (21.5) 
Mixed 51 (12.6) 29 (23.2) 80 (15.0) 
Muscle tension dysphonia (MTD) 
Yes 19 (4.7) 21 (16.8) 40 (7.5) 
No 387 (95.3) 104 (83.2) 491 (92.5) 
Family history 
Yes 43 (10.6) 19 (15.2) 62 (11.7) 
No 363 (89.4) 106 (84.8) 469 (88.3) 
Neurological problems 
Yes 42 (10.3) 17 (13.6) 59 (11.1) 
No 364 (89.7) 108 (86.4) 472 (88.9) 
Psychiatric problems 
Yes 46 (11.3) 16 (12.8) 62 (11.7) 
No 360 (88.7) 109 (87.2) 469 (88.3) 
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LD – laryngeal dystonia; LD/VT – laryngeal dystonia and voice tremor; st.dev. - standard 
deviation 
 
   The use of alcohol was reported by the majority of patients who participated in the online 
survey, including 374 (92.1%) of LD and 109 (87.2%) of LD/VT patients, with a good tolerance 
(all p ≤ 0.0001) (see Table 3). In the survey dataset, the majority of LD patients (34%) consumed 
alcohol occasionally, as compared to daily (25.4%) and weekly (25.9%) intake (p ≤ 0.0001), while 
the pattern of consumption (i.e., daily, weekly, occasionally) did not significantly differ in LD/VT 
patients (p = 0.031). No differences in alcohol consumption (χ2 = 0.036, p = 0.99) and tolerance (χ2 
= 3.80, p = 0.15) were found between the two groups; however, LD patients showed a tendency to 
more alcohol consumption (on average 2 drinks, 42.8% of patients) compared to on average 1 drink 
by LD/VT (50.5% patients) (p = 0.026) (see Table 3). This pattern of alcohol consumption in LD 
and LD/VT patients is higher compared to 64% of regular or infrequent drinkers in general adult 
population.(74)  
 
Table 3. Demographics of alcohol use 
Other major medical problems 
Yes 64 (15.8) 23 (18.4) 87 (16.4) 
No 342 (84.2) 102 (81.6) 444 (83.6) 
Treatment types 
Botulinum toxin injections 337 (83.0) 111 (88.8) 448 (84.4) 
Voice and speech therapy 275 (67.7) 84 (67.2) 359 (67.6) 
Other medications 71 (17.5) 43 (34.4) 114 (21.5) 
Laryngeal surgery 22 (5.4) 9 (7.2) 31 (5.8) 
Deep brain stimulation (DBS) 0 1 (0.8) 1 (0.2) 
Satisfaction with treatment 
Very satisfied 128 (31.5) 27 (21.6) 155 (29.2) 
A little satisfied 126 (31.0) 51 (40.8) 177 (33.3) 
Not satisfied 126 (31.0) 42 (33.6) 168 (31.6) 
No response 26 (6.4) 5 (4.0) 31 (5.8) 
 337 (100%) 111 (100%) 448 (100%) 
Satisfaction with Botulinum toxin 
A lot 187 (55.5) 39 (35.1) 226 (50.4) 
A little 101 (30.0) 48 (43.2) 149 (33.3) 
Not at all 47 (13.9) 24 (21.6) 71 (15.8) 
No response 2 (0.6) 0 2 (0.4) 
 LD Within 
group 
p-value 
(CI) 
LD/VT Within 
group 
p-value 
(CI) 
Between
-group  
p-value 
Total 
Patients 
 406 (100%)  125 (100%)   531 (100%) 
Alcohol use 
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Values in parenthesis provide the percent of total population, which is depicted above in the 
corresponding gray shaded area. CI - confidence interval; LD – laryngeal dystonia; LD/VT – 
laryngeal dystonia and voice tremor 
 
Improvement of LD symptoms following alcohol ingestion was noticed by 227 patients 
(55.9% of all LD patients or 60.7% of those who drank alcohol) (p ≤ 0.0001), while 130 patients 
(32.0% of all LD patients or 34.8% of those who drank alcohol) had no changes, and 14 patients 
(3.4% of all LD patients or 3.7% of those who drank alcohol) had worsening of their voice 
symptoms. Three patients (0.8%) were not sure about the effects of alcohol on the quality of their 
voice (see Table 4). In the survey dataset, the amount of alcohol required to see the best response 
was on average 2 drinks in 43.5% of LD patients (p = 0.002) with the duration of effect from 1-3 
hours (p ≤ 0.0001). The degree of symptom improvement following the alcohol intake varied from 
slightly (25.2% of LD patients) to mildly (30.4%) to strong (43.5%) with the majority of patients 
reporting noticeable symptom improvement following 2 drinks (43.5%). While there is a possibility 
that patient’s judgment of symptom severity might have been affected by alcohol consumption, this 
possibility, however, appears to be minimal considering that symptom improvement was also 
Yes 374 (92.1) <0.0001 
(0.89 - 
0.95) 
109 (87.2) <0.0001 
(0.81 - 
0.93) 
0.09 
483 
(91.0) 
No 32 (7.9) 16 (12.8) 48 (9.0) 
 374 (100%)  109 (100%)   483 (100%) 
Daily use 
Daily 95 (25.4) 
<0.0001 
27 (24.8) 
0.031 0.99 
122 
(25.3) 
Weekly 97 (25.9) 28 (25.7) 125 
(25.9) 
Occasionally 127 (34.0) 38 (34.9) 165 
(34.2) 
Special occasions 55 (14.7) 16 (12.8) 71 (14.7) 
Amount used 
1 drink 135 (36.1) 
<0.0001 
55 (50.5) 
0.0002 0.026 
190 
(39.3) 
2 drinks 160 (42.8) 34 (31.2) 194 
(40.2) 
> 2 drinks 75 (20.1) 20 (18.3) 95 (19.7) 
No response 4 (1.0) 0 4 (0.8) 
Tolerance of alcohol 
Well 163 (43.6) 
<0.0001 
38 (34.9) 
<0.0001 0.15 
201 
(41.6) 
OK 165 (44.1) 54 (49.5) 219 
(45.3) 
Poorly 37 (9.9) 16 (14.7) 53 (11.0) 
No response 9 (2.4) 1 (0.9) 10 (2.1) 
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noticed by a family member and/or friends in 214 (57.2%) LD patients (p = 0.003), which is 
comparable to patients’ self-reports. 
 
Responses to alcohol intake in the LD/VT group were reported by 73 patients (58.4% of all 
LD/VT patients or 67% of those who drank alcohol), who observed better quality of voice from 
slight (20.3%) to mild (24.3%) to strong (52.7%) improvement lasting 1-3 hours (55.4%) (all p ≤ 
0.001) (see Table 4). Furthermore, in the survey dataset, friends and relatives of 63.3% of LD/VT 
patients noticed their voice symptom improvement (p = 0.002). However, in contrast to the LD 
group, LD/VT patients did not report a significant amount-dependent response, that is changes in 
voice symptoms were relatively equally seen following 1 drink (33.8% patients), 2 drinks (36.5% 
patients) or more than 2 drinks (25.7% patients) (p = 0.48). As means to improve the voice quality, 
a significant portion of patients in both groups (45.2% LD and 53.2% LD/VT) reported that they 
used alcohol at least sometimes in professional/social situations in order to self-manage their 
symptoms (all p ≤ 0.001).  
 
Table 4. Effects of alcohol on voice symptoms in LD and LD/VT 
 LD 
Within-group 
p value 
(CI) 
LD/VT 
Within-group  
p value 
(CI) 
Between- 
group 
p-value 
 Total: 406 (100%) 
Total drinking LD: 374 (100%) 
Total: 125 (100%) 
Total drinking LD/VT: 109 
(100%) 
 
Response noticed by patient 
Better 227 (55.9/60.7) 
<0.0001 
73 (58.4/67.0) 
<0.0001 0.09 Worse 14 (3.4/3.7) 0 No change 130 (32.0/34.8) 35 (28.0/32.1) 
Unknown 3 (0.7/0.8) 1 (0.8/0.9) 
 230 (100%)*  74 (100%)*   
Degree of response 
Slightly 58 (25.2) 
0.002 
15 (20.3) 
0.001 0.31 Mildly 70 (30.4) 18 (24.3) A lot 100 (43.5) 39 (52.7) 
Unknown 2 (0.9) 2 (2.7) 
Amount required to see a response 
1 Drink 61 (26.5) 
0.002 
25 (33.8) 
0.48 0.41 2 Drinks 100 (43.5) 27 (36.5) > 2 Drinks 63 (27.4) 19 (25.7) 
Unknown 6 (2.6) 3 (4.1) 
Does drinking more make voice better 
Yes 159 (69.1) <0.0001  
(0.63 - 0.75) 
48 (64.9) 0.003  
(0.54 - 0.75) 0.59 No 65 (28.3) 23 (31.1) Unknown 6 (2.6) 3 (4.1) 
Duration of effect 
< 1 hour 24 (10.4) <0.0001 13 (17.6) <0.0001 0.09 
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* - Data are pulled from the patients who responded “Better” and “Unknown” in the category “Response 
Noted by Patient” 
** - Data are pulled from the total of patients who reporting drinking alcohol 
*** - Data are pulled from the total of all patients 
Values in parenthesis provide the percent of total population, which is depicted above in the 
corresponding gray shaded area. CI - confidence interval; LD – laryngeal dystonia; LD/VT – laryngeal 
dystonia and voice tremor 
  
Discussion 
Laryngeal dystonia, as the other forms of focal dystonia, is a multifactorial disorder of 
unclear pathophysiology, the gold standard treatment of which is currently considered repeated 
botulinum toxin injections into the laryngeal muscles. Alcohol has been previously reported as a 
potent pharmacological agent alleviating the symptoms of other movement disorders, such as 
tremor, including VT (9, 10, 75-77), and myoclonus-dystonia.(78-81) Although systematic studies of 
alcohol effects in primary dystonia have not been, to date, reported, single cases of writer’s 
cramp(82) and generalized dystonia(83) have been described to significantly benefit from alcohol 
consumption. In the current large study of 531 patients, we observed that over 55% of patients with 
LD alone and over 58% of patients with combined LD/VT reported significant positive effects of 
alcohol on their voice symptoms, such as voice breaks and tremor. Patients’ self-reported 
improvement of voice symptoms following alcohol intake was substantiated by similar observations 
made by their friends and/or family members, which minimizes the possibility of false positive 
subjective responses by patients, due, in part, to potentially reduced accuracy of patient’s judgment 
secondary to alcohol consumption. Our survey data further showed that symptoms of isolated LD 
1 - 3 hours 159 (69.1) 41 (55.4) 
> 3 hours 43 (18.7) 18 (24.3) 
Unknown 4 (1.7) 2 (2.7) 
 374 (100%)**  109 (100%)**   
Response noticed by family 
Yes 214 (57.2) 0.003  
(0.52 - 0.62) 
69 (63.3) 0.002 
(0.54 - 0.72) 0.17 No 157 (42.0) 37 (33.9) Unknown 3 (0.8) 3 (2.8) 
Use of alcohol to help with voice in social or professional situation 
Always 33 (8.8) 
<0.0001 
10 (9.2) 
<0.0001 0.31 Sometimes 136 (36.4) 48 (44.0) Never 194 (51.9) 48 (44.0) 
Unknown  11 (2.9) 3 (2.8) 
 406 (100%)***  125 (100%)***   
If a medication were available, would you consider taking it? 
Yes 390 (96.1)  118 (94.4)   
No 4 (1.0) 6 (4.8) 
Unknown 12 (3.0) 1 (0.8) 
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respond to alcohol intake and such responsiveness of patients with focal dystonia is not attributed to 
the presence of VT, which is known to improve following alcohol ingestion.(9, 10) In the majority of 
patients with LD alone, the symptoms were modulated in dose-dependent manner, i.e., positive 
effects were noticed following on average 2 drinks, whereas improvement of combined LD/VT 
symptoms appeared not to be contingent upon consumed amount of alcohol. Such an effect may be 
due, in part, to distinct influences of alcohol on pathophysiology of LD vs. LD/VT.  
 
Interestingly the improvement of voice symptoms to alcohol ingestion is similar to that 
achieved by BoNT (55.5%). The reasons for this are unclear as currently very little is known about 
the central effects of Botulinum Toxin (BoNT). It is thought that BoNT may indeed act centrally via 
either crossing the blood brain barrier or via retrograde transport via propriospinal pathways.(84) In 
the neuroimaging literature there is also conflicting data regarding the central role of BoNT. In the 
first, BoNT treatment did not result in reversal of the fMRI changes seen within the sensorimotor 
cortex in SD patients.(12) In the second study, H2150 PET was used to compare changes in regional 
cerebral blood flow (rCBF) with BoNT treatment. This found that activity in sensorimotor cortex 
was indeed abnormal in SD patients and subsequently was reversed with BoNT treatment.(85) Given 
the discrepancy between these studies, further research is required. This is currently being done 
within the Simonyan Dystonia laboratory, where both SD and SD/VT patients undergoing BoNT 
treatment are being assessed by multimodal neuroimaging including fMRI.  
 
While mechanisms of alcohol action in isolated dystonias are yet to be elucidated, its 
positive influences may be due to the direct modulation of GABAergic neurotransmission, which 
has been shown to be abnormal in dystonia.(23, 86-89) Taking into account that brain abnormalities in 
LD are not limited to the basal ganglia but include, in addition, the sensorimotor cortex and 
cerebellum(12-15, 39, 85), effects of alcohol on GABAergic transmission may also be exerted at 
multiple levels. Indeed, alcohol has been shown to potentiate GABA-mediated neurotransmission in 
the cortex of healthy subjects and patients with myoclonus-dystonia(90, 91), decrease cerebellar 
hyperactivity in patients with essential tremor(92), and directly elevate the dopamine level in the 
nucleus accumbens in the rat.(93) Thus, beneficial effects of alcohol on LD symptoms might be a 
result of complex modulations of different subsystems contributing to the pathophysiology of LD. 
Future studies need to examine this assumption in detail. 
 
While the findings of this study provide the first insights into alcohol-responsiveness of LD, 
the study limitations should be noted. First, 26.2% survey inclusion rate might represent a potential 
bias by not accounting for patients who check their emails less frequently and who are less inclined 
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to participate in online surveys. Next, the use of the online survey as a tool for collection of 
patient’s information based on subjective self-reports may be viewed as another study limitation. 
On the other hand, the conduct of online surveys in rare disorders such as LD might prove in some 
instances to be important for capturing data in a large patient population, which is typically 
unattainable within a short time frame if based on data from single clinical centers. Taking into 
account these limitations, our findings are in line with earlier epidemiological studies in LD, 
reflecting general demographics of surveyed patients. This includes the prevalence of LD in 
females, predominant ADLD subtype, the mean range of patients at around 60 years, and co-
occurrence of VT in about one-third of LD patients.(5, 7, 64, 94) We also found that 11.7% of all 
surveyed patients had one or more family members affected with LD or other forms of dystonia, 
which is similar to a previous report of 12%.(66) Finally, we observed similar demographic 
characteristics in an independent group of 126 LD (age: 55.0±12.7 years old) and 52 LD/VT (age: 
59.9±10.9 years old) patients who were seen in our clinic between 2009 and 2014 and underwent 
detailed examination of their voice symptoms for the participation in other studies. Specifically, 
these patients also had a female:male ratio of 3:1 in the LD group and 7:1 in the LD/VT group, 
predominant subtype of ADLD in 72.2% of LD patients and 75% of LD/VT patients and a family 
history of dystonia in 18% of all patients (unpublished data). Notably, these independent groups of 
patients reported similar levels of symptom improvement following alcohol consumption (54.8% in 
LD and 50% in LD/VT) as observed in the present study.  A future similar survey developed by a 
qualitative research team including clinicians and patients alike would no doubt strengthen these 
findings.  
 
In conclusion, the findings of our survey point to alcohol as a possible novel therapeutic 
agent for LD. However, because continuous consumption of alcohol may lead to abuse and 
dependency, self-medication or the prescription of alcohol for treatment of this disorder will remain 
undesirable. Instead, novel drugs mimicking the alcohol effects and increasing GABAergic 
neurotransmission, such as sodium oxybate(21) and octanoic acid(95), may lend new therapeutic 
opportunities for treatment of LD both with and without VT. 
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Chapter 3 – The Use of the Novel Therapeutic Agent Xyrem® on SD – A Case Series & 
Literature Review 
Introduction 
It has been anecdotally noted that the symptoms of SD often positively respond to the 
ingestion of alcohol. Recently this was confirmed in the literature by a large survey of SD patients 
by Kirke et al.(96) In this study it was found that 92.1% of SD patients consumed alcohol and of this 
group a further 55.9% saw an improvement in their disorder after alcohol use. To move past the 
assumption that the patient’s judgment may have possibly been clouded by alcohol use, patients 
reported that their family and friends also saw a positive impact on disease symptoms (57.2%). 
While many patients did admit to the use of alcohol in professional and social situations in order to 
improve their symptoms, this in the long term may indeed be problematic. As such the use of a 
similar but safer medication is desirable. Sodium oxybate or Xyrem® (Jazz Pharmaceuticals) is 
such a drug and is the sodium salt of gamma-hydroxybutyric acid (GHB). Following oral ingestion 
this crosses the blood brain barrier and is converted into gamma-aminobutyric acid (GABA).(17) As 
an ethanol analogue it has been successfully trialed in a single blinded setting in other alcohol 
responsive movement disorders.(18-20) Furthermore the use of this medication has also been extended 
to SD with the trial of Xyrem® in a single SD patient.(21) The results of this were promising and as 
such in this case series a further three subjects were analyzed and the assessment process formalized 
to not only include self-assessment, but also single blinded speech therapy assessment of breaks, 
harshness and breathiness. The hypothesis is that sodium oxybate will result in an improvement in 
both self-assessment of symptoms, as well as in blinded speech therapy assessment in those who 
already see a positive effect of alcohol on the clinical manifestations of their disease process. This 
may result in the extension of its use as either an adjunct to BoNT or a novel therapeutic treatment 
in its own right following further double blinded randomized controlled trials.   
 
Methods 
Patients 
A total of three patients were recruited from clinical practice at both the Icahn School of 
Medicine Mount Sinai Movement Disorders Center and the Head and Neck Surgical Group, New 
York, NY (age 44.33 ± 13.5; 2 males/1 female; 2 ADSD/1 ABSD). Extensive history and physical 
examination via fiber optic nasoendoscopy was undertaken prior to the study in order to confirm the 
patient diagnosis. Alcohol responsiveness was assessed by patient self report and further confirmed 
by at least a family member and/or friend. Each of the three patients reported improvement in SD 
symptomatology following at least one standard drink (defined as a 12 – ounce can of beer, 6 ounce 
glass of wine and/or 1 ounce shot of hard liquor). 
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Study Design – Inclusion & Exclusion Criteria 
Eligible subjects included adult (21-80 years old) patients with SD. Subjects receiving 
BoNT only participated in the study at the end of their treatment cycle, which was at least 3 months 
post injection. No participant had a history of other neurological, cognitive or psychological 
problems. Prior to participation all subjects gave written informed consent, which was approved by 
the Institutional Review Board of the Icahn School of Medicine at Mount Sinai. Inclusion and 
exclusion criteria are explicitly defined, as follows: -  
 
Inclusion criteria: -   
1. Clinically documented diagnosis of SD with positive effects of alcohol on symptoms. 
2. Age from 21 to 80 years. 
3. Native English speakers. 
 
Exclusion criteria: -   
1. Subjects who were incapable of giving an informed consent. 
2. Pregnant and breastfeeding women. All patients of childbearing potential were required to agree 
to use a reliable method of contraception prior and during the treatment with sodium oxybate. 
The method of contraception was documented in the patient’s research chart. All women of 
childbearing potential underwent a urine pregnancy test, which was negative for study 
participation. 
3. Subjects with past or present medical history of  (a) any neurological disorders, except for SD, 
were excluded from the study in order to maintain the homogenous patient population, allow for 
the evaluation of drug effect on CNS without confounding the presence of other neurological 
conditions. Patients who reported other past or present neurological problems, such as stroke, 
movement disorders other than SD, brain tumors, traumatic brain injury with loss of 
consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, 
drug dependence were excluded. All patients who had dystonic movements in other body 
regions apart from the larynx were excluded from the study; (b) psychiatric problems, such as 
schizophrenia, major and/or bipolar depression, obsessive-compulsive disorder, were excluded 
to maintain the homogenous patient population and allow for the evaluation of drug effect on 
CNS (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and 
polyps, carcinoma, chronic laryngitis; (d) known past or present history of hepatic and renal 
	 55	
dysfunction; (e) known past or present history of moderate to severe congestive heart failure; (f) 
known past or present history of cognitive impairment and active suicidal ideations.  
4. Patients who were not symptomatic due to treatment with BoNT injections into the laryngeal 
muscles. The duration of positive effects of BoNT vary from patient to patient but lasts on 
average for 3-4 months. All patients were evaluated to ensure that they were fully symptomatic 
prior to the entering the study. 
5. To avoid the possibility of confounding effects of drugs acting upon the central nervous system, 
all study participants were questioned about any prescribed or over-the-counter medications as 
part of their initial intake screening. Those patients who received medication(s) affecting the 
central nervous system (except sodium oxybate) were excluded from the study.  
 
Study Design - Procedure 
 Prior to Xyrem® administration all patients underwent several baseline testing measures 
including 1) a personal self assessment of their symptoms on a 9 point visual analogue scale, 2) 
cognitive testing via the Mini Mental Status Examination (MMSE) and the Montreal cognitive 
assessment (MoCA) (97, 98) 3) a measure of daytime sleepiness, the Epworth sleepiness scale (ESS) 
(99) 4) risk factor assessment for suicidality via the Columbia – Suicide Severity Rating Scale (C-
SSRS) (100) 5) assessment of vital signs and 6) videotaped voice recording using speech production 
tasks symptomatic for either ADSD (e.g. “Tom wants to be in the army” and/or ABSD (e.g. “He is 
hiding behind the house”).(64) A dose of 1gm – 1.5gm of Xyrem® was administered orally and the 
above testing was repeated approximately 40 minutes after ingestion. During this 40 minute period 
the patients were under constant visual monitoring and repetitively asked about side effects they 
were experiencing, which was also marked on a checklist. Side effects questioned about included 
dizziness, headache, nausea, depression, confusion, drowsiness and weakness, clumsiness or trouble 
concentrating, nausea, feeling "hung-over", nervousness or restlessness, and stomach pain. All side 
effects were documented in the patient research chart and reported to the Mount Sinai IRB and later 
to the FDA. By the end of their fifth hour of the visit, the testing measures were again repeated and 
if there was no change from the baseline examination the patient was discharged by a medical 
doctor into the care of a family member and/or friend. 
 
Data Analysis 
 All speech recordings were anonymized and randomized and then blindly rated by an 
experienced speech and language therapist. SD symptoms were assessed by counting the number of 
SD characteristic voice breaks.(64) Furthermore harshness and breathiness of voice was also assessed 
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by using a 100-point visual analogue scale (0 for none, 100 for most severe/profound, 100mm in 
length).  
 
Literature Review  
The active metabolite of the sodium oxybate (Xyrem®) is gamma-hydroxybutyic acid 
(GHB), which like ethanol crosses the blood brain barrier and is converted into GABA. It then 
exerts some of its major pharmacologic effects by acting at GABAB receptors, but its effects at 
GABAA receptors and other aspects of its pharmacology, including how it produces an effect on 
cataplexy, are still unknown.(17) It has a half-life of 0.5 to 1 hour, with less than 5% of the drug 
appearing in urine within 6 to 8 hours after dosing.(101) In 2002 Xyrem® was approved by the FDA 
for use in narcolepsy and given the drug has an abuse potential, all patients and their prescribers are 
enrolled in the Xyrem® Risk Evaluation & Mitigation Strategy (REMS) Program formally known 
as the Xyrem® Success Program (https://www.xyrem.com/healthcare-professionals/xyrem-rems-
program). This is a central registry that controls the distribution and administration of Xyrem® in 
order to prevent potential abuse and drug diversion.(102)  
 
Previous studies in the use of this drug have been conducted on patients with other ethanol 
responsive disorders, including post hypoxic myoclonus (PHM), myoclonus dystonia (MD) and 
essential tremor (ET).(18-20) In the first study, Xyrem® was considered as an alternative for a patient 
with PHM who was not responding to standard anti-myoclonic medications including clonazepam, 
valproic acid, phenobarbital, topiramate, levetiracetam and zonisamide. Prior to the trial with 
Xyrem® a standard glass of alcohol was administered in order to assess ethanol responsiveness. 
This demonstrated a significant improvement in the patient’s symptoms and as such Xyrem® was 
administered initially at 1 gram twice daily. This dose was increasingly titrated over the course of 
eight weeks to 4 grams twice daily, in order to establish the best dose for the patient. This 
improvement was based on blinded assessment of the Unified Myoclonus Rating Scale (UMRS), 
which measures the severity and intensity of myoclonus.(103) While patients with narcolepsy 
normally take between 4.5 – 9 grams of sodium oxybate, improvements in action myoclonus and 
functional performance improved in a dose dependent manner once the dosage reached 2 grams 
administered twice daily. The maximal benefit was seen at one hour post ingestion and the total 
effect time lasted approximately 3.5 hours.(18) In another similarly designed study, Xyrem® had a 
positive effect on a total of five patients with ethanol responsive disorders that included once again 
one patient with PHM, as well as two patients with ε-sarcoglycan-linked myoclonus dystonia and 
two with ET.(19) This study design was then expanded to 20 patients, including all the previously 
mentioned conditions as well as two patients with progressive myoclonic epilepsy (PME).(20) Side 
	 57	
effects in all three of these papers included headache, dizziness and mild sedation. The first two 
symptoms did not result in a dose reduction of Xyrem®, but the later symptom of sedation resolved 
when a minor dose reduction of 0.5 grams was undertaken.(18-20) The obvious shortcomings of each 
of these studies were the administration of Xyrem® to patients in an open label fashion and thus the 
possible placebo effect of the agent; however clearly the only way to minimize this is via a larger 
double-blinded randomized controlled trial. An argument to counter the placebo effect was that 
there was a consistent dose dependent response to Xyrem® seen on each administration, as well as 
improvements seen on blinded symptom rating, such as that of myoclonus, minimizing additional 
investigator bias. 
 
In patients with SD+/-VT only a single patient case study has been reported and this was in 
a patient with both ADSD and vocal tremor (SD/VT).(21) This patient was also ethanol responsive 
and had been receiving regular BoNT injections that were successful in controlling her SD 
symptoms. A 1.0 gram trial of Xyrem® was administered and her symptoms abated for a total of 10 
months. Further administration has resulted in symptom free periods ranging from 1 week to 2 
months. To further understand the underlying neuropathophysiology of the central effect of sodium 
oxybate, fMRI was undertaken at three separate time periods. The first was prior to Xyrem® 
administration, the second was 90 minutes following drug intake and the last was at the 8-month 
mark following the initial administration. The pre – treatment fMRI demonstrated similar findings 
to not only what was reported in the neuropathophysiology component of this thesis, but also to pre 
– existing literature on the neuropathophysiologic alterations seen in SD, with increased brain 
activity seen bilaterally in sensorimotor cortical regions, basal ganglia and cerebellum.(13, 104) The 
first post – treatment scan demonstrated the converse, with decreased brain activity in the primary 
sensorimotor cortex, putamen and cerebellum. On the second post – treatment scan these changes 
still remained in the putamen and cerebellum but the activity in the primary sensorimotor cortex had 
normalized.(21) Similarly the shortcomings of this study were the open label administration of 
Xyrem® to a single patient and the possible placebo effect of the agent. However there was a clear 
neuropathophysiologic alteration seen on the post treatment fMRI that cannot be accounted for by a 
placebo effect. Therefore these studies demonstrated that there may be a role for Xyrem® in the 
treatment of ethanol responsive movement disorders. In order to further define the utility of sodium 
oxybate in the setting of SD+/-VT, the role of the drug in three further patients was analyzed.  
 
Case Series 
Patient Characteristics 
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 All patients were established to be ethanol responsive prior to enrolling in the study with 
their baseline characteristics otherwise outlined in Table 1. 
 
Table 1. Patient characteristics  
Subject No Diagnosis Gender Age Ethnicity Duration 
Of Disease 
(Years) 
Subject 1 ADSD M 58 Caucasian 35 
Subject 2 ABSD M 44 Caucasian 10 
Subject 3 ADSD F 31 Hispanic 8 
 
Patient Self-Assessment 
Two of the three patients saw an improvement in patient self-assessment. Data was missing 
from subject 1, who was one of the first to be recruited into the study. Subject 2 had a 25% 
improvement in symptoms while subject 3 had a 61.5% improvement (see Table 2). 
 
Table 2. Effect of Xyrem® on patient self-assessment 
Subject No Pre Xyrem® Post Xyrem® % Improvement 
Subject 1 NA NA NA 
Subject 2 4.00 3.00 25.00 
Subject 3 6.50 2.50 61.54 
Self-assessment of voice symptoms was assessed on a 9-point visual analogue scale.  
NA – Not applicable. 
 
Blinded Speech Assessment Of Breaks 
 Each of the three patients had a different response to Xyrem® when blinded speech and 
language assessment was undertaken. Subject 2 had a slight worsening of their breaks (-5.26%), 
subject 1 had a mild improvement (21.0%), while subject 3 had an overwhelming improvement 
(78.6%) (see Table 3). 
 
Table 3. Effect of Xyrem® on blinded speech assessment of breaks 
Subject No Pre Xyrem® Post Xyrem® % Improvement 
Subject 1 5.17 4.08 20.97 
Subject 2 0.95 1.00 -5.26 
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Subject 3 3.50 0.75 78.57 
Breaks were counted individually as described in the methods.  
 
Blinded Speech Assessment Of Harshness & Breathiness 
 Similarly the patients had a variable response to Xyrem® on their symptoms of harshness 
and breathiness when blinded speech and language assessment was performed. Subject 2 had 
neither improvement in harshness or breathiness, subject 1 had a marginal improvement in both 
symptoms (23.7% and 6.1% respectively) and subject 3 had a 49.5% improvement in harshness and 
66.2% in breathiness (see Tables 4 & 5). 
 
Table 4. Effect of Xyrem® on blinded speech assessment of harshness 
Subject No Pre Xyrem® Post Xyrem® % Improvement 
Subject 1 97.00 74.00 23.71 
Subject 2 0.00 0.00 0.00 
Subject 3 91.00 46.00 49.45 
Harshness was assessed by using a 100-point visual analogue scale as described in the  
methods. 
 
Table 5. Effect of Xyrem® on blinded speech assessment of breathiness 
Subject No Pre Xyrem® Post Xyrem® % Improvement 
Subject 1 49.00 46.00 6.12 
Subject 2 74.00 76.00 -2.70 
Subject 3 77.00 26.00 66.23 
Breathiness was assessed by using a 100-point visual analogue scale as described in the 
methods. 
 
Discussion 
These results build on the previously published and discussed article on the use of Xyrem® 
in a single patient with SD/VT, demonstrating that this novel drug may provide an adjunct or 
possibly an alternative to the standard of BoNT treatment.(21) In this case series two out of the three 
patients with SD alone saw varying degrees of improvement in blinded speech assessment of 
breaks, harshness and breathiness. The only side effect of the drug in this trial was light-headedness 
and dizziness in one patient (Subject 2), but these symptoms resolved within the 40-minute 
observational period following drug ingestion. There were no significant changes seen in 
comparison of pre and post Xyrem® cognitive function, ESS and suicidality. Despite the 
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occurrence of mild side effects, Subject 2 continued the drug after the study was completed and 
interestingly this was the patient that saw the least improvement on blinded speech assessment, but 
did see an improvement on personal self-assessment. This patient elected to get a prescription for 
Xyrem® in order to use the drug in a professional situation and thus provide himself with additional 
occupational confidence. In fact it is precisely this setting in which Xyrem® may have its greatest 
use, as it has been previously shown in the literature that SD has a negative impact on workplace 
productivity.(7) Furthermore it may have advantage over BoNT in this setting as it has a short half 
life (0.5 to 1 hour) and is metabolized rapidly with less than 5% of the drug appearing in the urine 6 
to 8 hours after dosing.(101) BoNT on the other hand is injected into either the adductor or abductor 
laryngeal musculature depending on the subtype of SD and is performed on average every three 
months precluding it from short term use.(2, 3, 8)  Currently the literature demonstrates that ADSD 
patients receive the greatest benefit from BoNT, ABSD a moderate benefit and VT a more 
unpredictable response.(3, 9) There were only three patients included in this case series and thus the 
research is currently unable to determine whether Xyrem® can benefit all subtypes of SD+/-VT. 
This will of course require larger open label studies and in the near future a double-blinded placebo 
controlled trial. The actual number of patients needed for such a trial can be inferred from previous 
fMRI studies in SD, as future research would also incorporate analysis of changes in brain 
activation before and after treatment.(13) In order to assess the central effects of sodium oxybate 
power analysis determined a sample size of 22 patients to have 80% power at 0.025 to detect 
changes. Therefore recruiting 25 ethanol responsive SD patients would account for subjects’ 
dropout possibilities and increase statistical power. Furthermore it would also be desirable to recruit 
the same amount of SD/VT subjects and thus compare the response, both clinically and centrally 
via fMRI, to sodium oxybate. 
 
Currently it is thought sodium oxybate may have some use in SD+/-VT because the levels 
of GABA are thought to be deficient in dystonia patients.(22, 23, 86) Like ethanol, Xyrem® crosses the 
blood brain barrier and is converted into GABA. (17) For this reason and like the previous research 
that has come before it, only alcohol responsive patients were trialed in this study. While the exact 
neuropathophysiological mechanisms of the effect of alcohol on dystonia are not well understood, 
one can hypothesize that there is influence of ethanol on the excitatory and inhibitory interplay of 
GABAergic neurotransmission. Finally the clear limitation of this study is that it is an open label 
trial and therefore one cannot rule out the placebo effect, however an argument to counter this 
includes the improvements seen in single blinded speech assessment. Given the promise of this case 
series there is no doubt however that once again a larger open label study followed by a double 
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blinded, placebo controlled trial will be required in order to further investigate the role of the 
sodium oxybate in the treatment of this disorder.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 62	
Conclusion & Future Directions 
SD+/-VT is a rare focal laryngeal dystonia affecting speech production that is both socially 
and occupationally disabling. It is indeed both under-diagnosed and therefore likely inadequately 
treated in many. While there has been much ground made in understanding the 
neuropathophysiology, aetiology and clinical phenomenology of the disorder it still remains a 
challenging condition to treat. This thesis therefore set to improve upon the current existing 
knowledge of SD+/-VT with the goal to ultimately lead to enhanced management of the disorder. 
This was achieved by embarking on three distinct aims of which this Masters of Philosophy did 
fulfill.  
 
The first aim was to better understand the neuropathophysiology of  SD+/-VT. While there 
had been recent discoveries regarding the brain functional and structural alterations in SD, the VT 
component of SD/VT had remained poorly understood, thus complicating the differential diagnosis 
and management of the disorders. Using advanced neuroimaging including fMRI, VBM and DWI it 
was found that SD and SD/VT were heterogeneous disorders at different ends of a clinical 
spectrum. The identification of characteristic neural signatures will no doubt help aid in improved 
diagnosis for these conditions in the future, as well as help identify treatment opportunities targeting 
specific brain abnormalities. This will be further achieved by doing specific neuroimaging analysis 
of the subtypes of SD including ADSD, ABSD and mixed SD. Furthermore an analysis of VT 
would also contribute in continuing to understand SD/VT. As we did in this study with SD and 
SD/VT, correlation analysis between subtype and severity as well as duration of disease would also 
assist in understanding the phenotype of the disease.  
 
The second aim was to further understand the clinical features of both SD and SD/VT by 
identifying the effect of alcohol on both subsets of patients. The positive effect of alcohol has been 
noticed anecdotally in SD patients with or without VT and has also been acknowledged in the 
literature in patients with VT alone but not in SD. By conducting a cross sectional analysis of 
alcohol intake and its effects on symptoms it was found that both SD and SD/VT respond positively 
to alcohol. Interestingly it was also found that SD responds in a dose dependent manner to alcohol 
intake, with SD patients requiring two drinks to see a positive effect. Conversely SD/VT symptoms 
do not appear to be contingent upon a certain consumed volume. Not only do these findings move 
our knowledge of the clinical features of SD+/-VT past anecdote but they also point to alcohol as a 
possible novel therapeutic agent for SD+/-VT. To further establish its role a future similar survey 
developed by a qualitative research team including clinicians and patients alike would no doubt 
strengthen these findings. Furthermore it would also be important to elucidate the neural correlates 
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of the benefits of alcohol in SD+/-VT. This could also be achieved by pre and post treatment 
multimodal neuroimaging.  
 
The third and final aim was to further explore the role of alcohol in SD patients as a possible 
novel pharmacological treatment via a case series and extensive literature review. This was 
undertaken by trialing sodium oxybate (Xyrem®), on three patients and examining the effect via 
patient self-assessment and single blinded speech assessment of breaks, harshness and breathiness 
both pre and post Xyrem® intake. Whilst not too many conclusions can be drawn from a cohort of 
three patients, some promise has been demonstrated in the use of sodium oxybate (Xyrem®) as a 
possible adjunct to BoNT or as a novel therapeutic treatment in its own right. The next logical 
progression will be to perform a larger open label study in the first instance followed by a double 
blinded, placebo controlled trial to further assess and analyze its use. Following this it would be 
important to repeat this trial in patients with SD/VT, as well as in the particular subtypes of SD 
(ADSD/ABSD/Mixed), as well as in VT itself. To ultimately understand the central role of sodium 
oxybate it would also be beneficial to investigate its pre and post treatment effects by multimodal 
neuroimaging. 
 
So in summary this Masters has achieved its aims by not only resulting in a better 
understanding of the neuropathophysiology and clinical features of SD with or without VT, but it 
has also laid the foundation for further exploration of novel therapeutic treatments. The findings of 
this thesis have also improved the differential diagnosis of these disorders by further extending our 
knowledge past anecdote and as such will ultimately lead to an improved management of these 
interesting conditions. 
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Addendum 
Addendum 1. Raw data for Chapter 1 
1. SD  
Patient 
No. 
Duration 
(Years) 
Onset 
(Years) 
Breaks R 
Putamen 
fMRI 
R 
Putamen 
VBM 
L IFG 
fMRI 
L IFG 
VBM 
L Putamen 
fMRI 
1 26 36 1.69 0.416174 0.527127 1.642018 0.499811 -0.015041 
2 35 23 4.03 0.217581 0.634341 0.708739 0.801752 -0.006058 
3 6 65 2.88 0.461533 0.539158 0.521241 0.546752 0.944502 
4 8 37 3.47 0.460543 0.522592 0.411832 0.565104 0.163438 
5 
4 44 2.91 0.168914 0.640445 
-
0.342949 0.805025 0.091359 
6 
13 42 4.57 
-
0.004117 0.559028 1.196839 0.677757 0.433442 
7 20 29 2.09 0.73526 0.670717 2.562695 0.624596 0.294267 
8 7 43 1.38 1.296599 0.883213 1.367466 0.705851 0.676767 
9 15 34 3.5 0.157972 0.462339 1.411346 0.465046 0.334306 
10 9 42 3.16 0.148574 0.567387 0.603397 0.628033 0.384863 
11 3 55 5.28 0.52239 0.541941 1.286026 0.670208 0.844632 
12 27 17 1.81 0.246298 0.621791 0.874558 0.748543 0.230667 
13 
20 36 2.56 
-
0.039088 0.639001 0.672716 0.629773 -0.338958 
14 5 45 3.85 -0.04887 0.458634 0.974453 0.619682 0.799293 
15 13 26 3.38 0.326612 0.69352 0.0089 0.776543 -0.11399 
16 18 46 3.19 0.342398 0.618704 0.245201 0.859075 0.41118 
17 12 58 1.94 0.203403 0.602954 0.409065 0.577039 0.398506 
18 20 38 3 0.17045 0.470204 0.668809 0.66826 0.28564 
19 
12 44 2.47 
-
0.075084 0.480951 1.013776 0.634326 0.073073 
20 2 53 1.78 0.449014 0.497667 1.271188 0.628479 0.239082 
fMRI values are % BOLD signal change, VBM values are Gray matter volume (l), Breaks were 
counted as described in the methods. 
 
2. SD/VT OR DTv 
Patient 
No 
Duration 
(Years) 
Onset 
(Years) 
Breaks Tremor L 
Putamen 
fMRI 
L 
Putamen 
VBM 
L IFG 
fMRI 
L IFG 
VBM 
1 6 58 3.91 55.75 0.635571 0.760616 0.499811 0.496107 
2 15 42 2.84 42.75 0.780299 0.766506 0.801752 0.572022 
3 5 51 2.53 95.50 0.707917 0.595172 0.546752 0.370385 
4 28 38 2.59 91.50 0.71563 0.782859 0.565104 0.538609 
5 10 68 1.66 56.00 0.792058 0.652038 0.805025 0.415918 
6 6 45 2.44 21.50 0.796228 0.639126 0.677757 0.62326 
7 16 51 2.34 62.25 0.863533 0.751848 0.624596 0.504292 
8 32 28 2.92 69.75 0.923081 0.742514 0.705851 0.415604 
9 9 34 1.81 28.75 0.547891 0.767117 0.465046 0.467849 
10 2 36 2.06 23.25 0.867335 0.848218 0.628033 0.581968 
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11 18 50 2.28 39.75 0.67439 0.618837 0.670208 0.415036 
12 23 44 2.59 68.75 0.854247 0.764065 0.748543 0.496662 
13 6 55 1.88 84.75 0.808926 0.735203 0.629773 0.435894 
14 5 56 1.56 86.75 0.647556 0.62877 0.619682 0.386969 
15 17 44 3.91 49.75 0.750449 0.694369 0.776543 0.331977 
16 10 60 2.13 0.00 0.765525 0.552161 0.859075 0.544195 
17 25 44 3.5 84.75 0.96136 0.588417 0.577039 0.46733 
18 3 58 2.5 34.00 0.6113 0.820365 0.66826 0.4701 
19 3 39 3.97 39.25 0.658283 0.668053 0.634326 0.442113 
20 10 50 4.65 49.75 0.777405 0.77645 0.628479 0.512442 
 
SD/VT or SD/DTv Continued 
Patient 
No 
R 
Putamen 
fMRI 
R 
Putamen 
VBM 
1 0.527127 0.600563 
2 0.634341 0.698933 
3 0.539158 0.546081 
4 0.522592 0.713716 
5 0.640445 0.650385 
6 0.559028 0.555947 
7 0.670717 0.648703 
8 0.883213 0.676205 
9 0.462339 0.771665 
10 0.567387 0.752446 
11 0.541941 0.587847 
12 0.621791 0.692991 
13 0.639001 0.628307 
14 0.458634 0.546727 
15 0.69352 0.72607 
16 0.618704 0.517935 
17 0.602954 0.553294 
18 0.470204 0.666031 
19 0.480951 0.573442 
20 0.497667 0.672943 
fMRI values are % BOLD signal change, VBM values are Gray matter volume (l), Breaks and DTv 
symptoms were counted as described in the methods. 
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